IRIS
MINARI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.088
AS - Asia 2.845
EU - Europa 1.949
SA - Sud America 367
AF - Africa 168
OC - Oceania 3
Totale 8.420
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.007
SG - Singapore 915
IT - Italia 763
CN - Cina 605
VN - Vietnam 504
BR - Brasile 267
HK - Hong Kong 225
IE - Irlanda 216
BD - Bangladesh 210
SE - Svezia 173
DE - Germania 169
FR - Francia 114
ZA - Sudafrica 100
NL - Olanda 98
IN - India 91
RU - Federazione Russa 90
GB - Regno Unito 81
AT - Austria 56
FI - Finlandia 52
CA - Canada 47
AR - Argentina 40
TR - Turchia 35
JP - Giappone 32
KR - Corea 31
PH - Filippine 27
ES - Italia 26
ID - Indonesia 26
CI - Costa d'Avorio 24
PK - Pakistan 22
CZ - Repubblica Ceca 21
IQ - Iraq 20
PL - Polonia 19
MX - Messico 18
CO - Colombia 15
UZ - Uzbekistan 15
EC - Ecuador 14
UA - Ucraina 13
IR - Iran 12
BE - Belgio 11
MA - Marocco 10
VE - Venezuela 10
TW - Taiwan 9
JO - Giordania 8
LT - Lituania 8
SA - Arabia Saudita 8
TN - Tunisia 8
EG - Egitto 7
LU - Lussemburgo 7
PY - Paraguay 7
CL - Cile 6
KZ - Kazakistan 6
MY - Malesia 6
TH - Thailandia 6
BG - Bulgaria 4
IL - Israele 4
NP - Nepal 4
RO - Romania 4
SN - Senegal 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
AZ - Azerbaigian 3
DK - Danimarca 3
GT - Guatemala 3
KE - Kenya 3
LB - Libano 3
MK - Macedonia 3
PE - Perù 3
PS - Palestinian Territory 3
AL - Albania 2
BO - Bolivia 2
BW - Botswana 2
CG - Congo 2
ET - Etiopia 2
GE - Georgia 2
GY - Guiana 2
JM - Giamaica 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
SV - El Salvador 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
Totale 8.410
Salva come PNG Salva come JPEG
Città #
Singapore 534
Ashburn 510
Dallas 447
San Jose 304
Dublin 210
Hong Kong 209
Chandler 200
Parma 174
Santa Clara 168
Ho Chi Minh City 152
Boardman 132
Hanoi 122
Beijing 119
Los Angeles 100
Johannesburg 93
Milan 93
Munich 90
Ann Arbor 84
New York 80
Shanghai 79
Hefei 76
Council Bluffs 55
Lauterbourg 55
Bologna 47
Chicago 47
Vienna 44
Buffalo 35
Moscow 34
Marseille 29
São Paulo 28
Verona 27
Da Nang 25
Abidjan 24
Rome 24
London 23
Princeton 22
Seoul 22
Tokyo 22
Frankfurt am Main 21
Atlanta 20
Nuremberg 19
Denver 18
Helsinki 18
Dearborn 17
Turku 17
The Dalles 16
Warsaw 16
West Jordan 16
Amsterdam 15
Columbus 15
Jakarta 15
Bengaluru 14
Bremen 14
Haiphong 14
Montreal 14
Brno 13
Modena 13
Toronto 13
Chennai 12
Rio de Janeiro 12
Stockholm 12
Brussels 11
Izmir 11
Lahore 11
Orem 11
Pune 11
Seattle 11
Brescia 10
Des Moines 10
Houston 10
Istanbul 10
Manchester 10
Poplar 10
Tashkent 10
Wilmington 10
Buenos Aires 9
Phoenix 9
Redondo Beach 9
Amman 8
Belo Horizonte 8
Biên Hòa 8
Chongqing 8
Düsseldorf 8
Nanjing 8
Bari 7
Boston 7
Brasília 7
Brooklyn 7
Changsha 7
Charlotte 7
Florence 7
Fremont 7
Jinan 7
Kolkata 7
Mumbai 7
Palermo 7
Pavia 7
Ravenna 7
Shenyang 7
Auburn 6
Totale 5.225
Salva come PNG Salva come JPEG
Nome #
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 264
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 251
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 244
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 218
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 215
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 208
227P Sexual dimorphism in immune profile of early and advanced NSCLC 202
Evidence fo Epigenetic Abnormalities of the Androgen Receptor Gene in Foreskin from Children with Hypospadias 202
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 202
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 197
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 195
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 184
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 178
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 176
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 174
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 167
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 167
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 165
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 163
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 163
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 157
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 157
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 156
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 155
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 154
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 151
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 151
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 150
A novel mutation in the nr0b1 gene in a family with monozygotic twin sisters and congenital adrenal hypoplasia affected children. 149
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 145
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 144
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 142
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 139
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 136
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 136
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 134
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 131
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 129
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 129
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 121
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 119
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 118
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 115
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 112
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 110
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 107
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 105
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 101
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 97
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 95
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 94
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 92
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 92
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 85
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 79
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 78
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 66
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 58
Resistenze al flusso delle vie aeree e reattanza polmonare in bambini affetti da obesità e asma 2
Totale 8.526
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202115 0 0 0 0 0 0 0 0 0 0 0 15
2021/2022215 19 8 10 16 11 2 43 10 17 3 20 56
2022/2023849 67 84 37 73 83 87 15 64 242 7 61 29
2023/2024656 30 24 15 28 58 89 62 35 36 70 86 123
2024/20251.895 101 105 144 152 165 146 151 108 170 165 164 324
2025/20264.598 376 372 692 419 470 236 414 190 607 352 338 132
Totale 8.526